SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-050063
Filing Date
2020-02-26
Accepted
2020-02-26 16:05:52
Documents
12
Period of Report
2020-02-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d892673d8k.htm   iXBRL 8-K 23699
  Complete submission text file 0001193125-20-050063.txt   142359

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fprx-20200224.xsd EX-101.SCH 3072
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20200224_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20200224_pre.xml EX-101.PRE 10954
10 EXTRACTED XBRL INSTANCE DOCUMENT d892673d8k_htm.xml XML 3258
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 20655668
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences